Enterprise Europe Network

Endothelial microvesicles with microbicidal effect for the preparation of a medicament or for a direct use.

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20181015004
Published
15/10/2018
Last update
24/10/2019
Expiration date
01/05/2020

Keywords

Partner keyword: 
Medical Research
Microbiology
Drug delivery and other equipment
EXPRESS YOUR INTEREST

Summary

Summary: 
A research group from a Spanish university has developed endothelial microvesicles with microbicidal effect. These vesicles destroy the main pathogens involved in sepsis and even strains derived from them resistant to multiple antibiotics. The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R&D institutions interested in the design of new medicines.

Description

Description: 

Sepsis is one of the leading causes of mortality worldwide. 20 to 30 million cases of sepsis are registered annually in the world, with 50 people being killed every hour.
Annually, it affects 50,000 people in Spain, of whom 17,000 die. In the last ten years, cases of sepsis have doubled and studies believe that the trend will continue to be high.
Recent studies on sepsis and infection in vivo have seen a great increase of microvesicles (MV) in blood and have studied the utility of said MV for the differentiation between other pathologies of bacterial origin. MVs play an important role in the defense against pathogens that are therefore beneficial as part of the natural response to infection.
The present invention, therefore, refers, as a first aspect, to the use of endothelial microvesicles (MVe) to make a new medicament (preferably an antibiotic), since they possess a potent antimicrobial capacity both on the main pathogens involved in sepsis as well as on multiresistant bacterias to the conventional antibiotics. These MVs cause the destruction of bacteria but do not affect eukaryotic cells. Alternatively, the present invention also relates to MV derived from endothelial cells for its use as a medicament.
This new function discovered about the MV is of great diagnostic utility and also offers a wide variety of therapeutic targets, as well as an alternative to antibiotics for the treatment of infectious pathologies such as sepsis. That bactericidal action of the MVe of the invention is carried out even at physiological concentrations, and with a high concentration of microorganisms, specifically bacteria, being this action stronger when higher is the concentration of MVe.
The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R&D institutions interested in the design of new medicines.

Advantages & innovations

Cooperation plus value: 
- Use of endothelial microvesicles as an alternative to antibiotics. - The treatment with the MVe of the invention does not induce physiopathological changes in eukaryotic cells. - The antimicrobial activity associated with the MVe of the invention is not dependent on the complement line and is very stable. - The MVe have bactericidal activity both against Gram-type bacteria and against Gram + bacteria. - The pharmaceutical composition of the present invention accepts to contain additives to increase, control or otherwise direct the desired therapeutic effect of the MVe of the invention (buffering agents, surfactants, cosolvents, preservatives, etc ...) - The pharmaceutical composition can be administered by conventional means: intravenously, trocars, cannulae. And, in addition, it allows direct administration by injection, on the external surface of the affected organ or tissue. - The pharmaceutical composition can be stored up to the moment of its application by conventional methods known to those skilled in the art. - It is resistant to freezing and thermal treatments up to 85ÂșC. - They have also been shown to be effective against the biofilms that form these microorganisms.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R&D institutions interested in the design of new medicines. Companies of the target sectors previously mentioned are sought to exploit the results of the invention via licensing and/or commercial agreements with technical cooperation. Research institutions or companies with a solid R&D background are sought for cooperation agreements in order to foster the technology already developed to a next stage.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500